Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:17 AM
Ignite Modification Date:
2025-12-25 @ 2:17 AM
NCT ID:
NCT04629560
Eligibility Criteria:
Inclusion Criteria:
* The inclusion criteria are the following:
* Patients over 18 years old with a life expectancy of 3 months or more.
* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
* At enrollment, patients must be able to take oral medications and food reliably without any risk factors for aspiration.
* Patients that have received at least 1 cycle of chemotherapy and have at least 1 more cycle planned.
* Patients receiving the following drug-containing chemotherapy regimens: cyclophosphamide, carboplatin, cisplatinum, gemcitibine, methotrexate, doxorubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, oxaliplatin, irinotecan and etoposide.
* Patients receiving radiotherapy at the time of chemotherapy are allowed, with the exception of patients receiving radiotherapy for head and neck tumors
* Patients with the ability to understand and the willingness to sign a written informed consent document written in English and answer all appropriate questionnaires in English or Spanish. (see Appendix 3)
* Patients with brain metastases are eligible if neurologically stable after appropriate treatment (surgery and/or radiation).
Exclusion Criteria:
* • Patient that have mechanical obstruction of the alimentary tract.
* Patients who have developed decreased/altered taste sensation for any reason besides chemotherapy
* Patients with malabsorption or intractable vomiting.
* Patients who have extensive dental caries
* Patients who have poor oral hygiene
* Patients receiving radiotherapy for head and neck tumors.
* Previous surgery that included ablation or removal of the olfactory component of the taste.
* Untreatable oral thrush.
* Women that are pregnant, nursing or of childbearing potential and unwilling to use contraception, as the effects of the miracle fruit on the developing human fetus are unknown.
* Patients with an ANC \< 500/uL .
* Patients with poorly controlled diabetes mellitus (DM) as determined by their primary physicians will be excluded from the study. All DM patients will be required to check their blood sugar on their usual home glucose meters at least once a day, prior to the ingestion of the miracle fruit. If the patient does not a glucose meter, we will provide the patient with one. Any case of hypoglycemia (blood sugar below 60) should be reported immediately to the treatment physician and the patient should stop the miracle fruit treatment.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04629560
Study Brief:
Protocol Section:
NCT04629560